# Sarepta Therapeutics Inc. (SRPT) fundamentals

Data as of 2026-11-05. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $18.99, market value $2.0 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Sarepta Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 1.4×**. Each dollar of revenue is priced at 1.4×.
- **Price / book: 1.3×**. The shares trade at 1.3× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 4.1%** (5-yr avg -6.6%). Free cash flow equals 4.1% of the market value, above its five-year average of -6.6%, so the shares are cheaper on cash than they have usually been.

## Profitability
- **Operating margin: -10.2%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -38.3%**. The company reported a net loss over the last twelve months.
- **Return on equity: -62.5%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -9.7%**. Return on all capital, debt included, is -9.7%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -4.1%**. Each dollar of assets produces -4.1% of profit.

## Growth
- **Revenue growth (1 yr): 4.3%** (3-yr 30.2%/yr, 5-yr 32.5%/yr). Revenue grew 4.3% over the last year, against 32.5% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -404.7%**. Earnings per share fell 404.7%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.73**. Debt is 0.73 times equity, moderate leverage.
- **Net debt / EBITDA: net cash**. Sarepta Therapeutics Inc. holds more cash than debt.
- **Current ratio: 2.32** (quick 2.32). Current assets cover the next year's liabilities 2.32 times.
- **Altman Z-score: 1.41**. A Z-score of 1.41 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Sarepta Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: hold** (22 analysts). 22 analysts cover Sarepta Therapeutics Inc.; the consensus is hold, with an average price target of $21.64 (+14% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 17.2%** (YTD -11.8%, 3-mo 19.2%). The shares are up 17.2% over twelve months including dividends.
- **From 52-week high: -23.1%** (29.4% above the low). Trading 23% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 2.04** (volatility 79%). Beta of 2.04 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SRPT · Page: https://foliofundamentals.com/stocks/srpt

Not investment advice.